Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics reported first quarter 2026 results and a major portfolio change. The company terminated its exclusive license with Overland covering four CAR T targets in parts of Asia, with no termination payments, and restructured its Overland ownership and governance; Allogene now expects to hold about 3% of Overland’s equity.
Interim data from the pivotal Phase 2 ALPHA3 trial showed 58.3% of patients on cemacabtagene ansegedleucel achieved minimal residual disease clearance versus 16.7% on observation, with a 97.7% median ctDNA reduction and no CRS, ICANS, GvHD, treatment-related serious events or hospitalizations. In autoimmune disease, nine patients have been treated in the Phase 1 RESOLUTION trial of ALLO-329 with early signs of activity and favorable tolerability.
Research and development expense was $32.0 million and general and administrative expense was $14.1 million, leading to a net loss of $42.6 million, or $0.18 per share. Allogene ended the quarter with $266.9 million in cash, cash equivalents and investments, and an April 2026 public offering added $200.4 million in gross proceeds, extending projected cash runway into the first quarter of 2029. The company now guides 2026 operating cash expense to about $165 million and GAAP operating expenses to about $225 million.
Allogene Therapeutics is asking stockholders to vote at its fully virtual 2026 annual meeting on June 18, 2026. The agenda includes electing three Class II directors, advisory votes on executive pay and pay vote frequency, and ratifying Ernst & Young LLP as auditor.
The company is also requesting approval of an Authorized Shares Amendment to double authorized common stock from 400,000,000 to 800,000,000 shares. The record date is April 20, 2026, when 345,024,351 shares of common stock were outstanding and entitled to vote.
Frazier-affiliated investors report shared ownership stakes in Allogene Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. holds 16,205,306 shares (4.7%). Related Frazier funds hold additional positions: 306,906 shares (0.1%), 722,956 shares (0.2%), and 1,561,500 shares (0.5%) in separate partnerships. The percent calculations reference 243,777,920 shares outstanding as of March 10, 2026 and incorporate 100,200,000 shares sold by the issuer on April 16, 2026.
Allogene Therapeutics SVP of Finance Annie Yoshiyama reported a small share sale mainly for tax purposes. She sold 9,586 shares of common stock in an open-market transaction to cover tax withholding obligations tied to the vesting of restricted stock units under a mandated “sell to cover” arrangement, rather than a discretionary trade. The weighted average sale price ranged from $2.31 to $2.33 per share. After this transaction, she directly holds 124,517 Allogene shares, which include 3,781 shares acquired on March 15, 2026 through an employee stock purchase program.
Allogene Therapeutics submitted a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit award. The vesting date shown is 04/20/2026 and the Form 144 filing line shows 04/21/2026.
Allogene Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on June 18, 2026 at 8:00 a.m. Pacific Time. Stockholders of record as of April 20, 2026 may vote on: election of three directors, advisory approval of executive compensation and frequency, an amendment to increase authorized common stock from 400,000,000 to 800,000,000 shares, and ratification of Ernst & Young LLP as auditor. The Board recommends FOR all proposals. The Board will reduce its size to ten members effective at the meeting and did not renominate Todd Sisitsky as part of planned succession and refreshment.
Allogene Therapeutics, Inc. is raising capital through an underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, for expected gross proceeds of $175 million before fees and expenses. The company granted underwriters a 30-day option to buy up to 13,125,000 additional shares at the same public price, less discounts and commissions. Allogene plans to use the net proceeds for general corporate purposes, including clinical trial, research and development, general and administrative costs, and capital expenditures. The offering is being made under an effective shelf registration on Form S-3 and is expected to close around April 16, 2026, subject to customary conditions.
Allogene Therapeutics, Inc. is offering 87,500,000 shares of its common stock at a public offering price of $2.00 per share by prospectus supplement dated April 14, 2026. The underwriting agreement shows proceeds, before expenses, to Allogene of $164,500,000. The underwriters have a 30‑day option to purchase up to an additional 13,125,000 shares at the public price less underwriting discounts. The offering assumes delivery in New York on or about April 16, 2026. The number of shares outstanding immediately after this offering is based on 229,413,523 shares outstanding as of December 31, 2025.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.